DE69423436D1 - An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie - Google Patents

An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie

Info

Publication number
DE69423436D1
DE69423436D1 DE69423436T DE69423436T DE69423436D1 DE 69423436 D1 DE69423436 D1 DE 69423436D1 DE 69423436 T DE69423436 T DE 69423436T DE 69423436 T DE69423436 T DE 69423436T DE 69423436 D1 DE69423436 D1 DE 69423436D1
Authority
DE
Germany
Prior art keywords
phospholipase
lipoprotein
tied
diagnosis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69423436T
Other languages
English (en)
Other versions
DE69423436T2 (de
Inventor
Houston Macphee
Graham Tew
Donald Southan
Mary Hickey
Simon Gloger
Mark Lawrence
Quentyn Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313144A external-priority patent/GB9313144D0/en
Priority claimed from GB9400413A external-priority patent/GB9400413D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE69423436D1 publication Critical patent/DE69423436D1/de
Publication of DE69423436T2 publication Critical patent/DE69423436T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
DE69423436T 1993-06-25 1994-06-24 An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie Expired - Lifetime DE69423436T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939313144A GB9313144D0 (en) 1993-06-25 1993-06-25 Compounds
GB9400413A GB9400413D0 (en) 1994-01-11 1994-01-11 Compounds
PCT/GB1994/001374 WO1995000649A1 (en) 1993-06-25 1994-06-24 Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy

Publications (2)

Publication Number Publication Date
DE69423436D1 true DE69423436D1 (de) 2000-04-20
DE69423436T2 DE69423436T2 (de) 2000-09-07

Family

ID=26303121

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69423436T Expired - Lifetime DE69423436T2 (de) 1993-06-25 1994-06-24 An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie

Country Status (5)

Country Link
US (13) US5981252A (de)
EP (2) EP0658205B1 (de)
JP (1) JPH08500740A (de)
DE (1) DE69423436T2 (de)
WO (1) WO1995000649A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
ATE315655T1 (de) * 1993-10-06 2006-02-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
US5977308A (en) * 1993-10-06 1999-11-02 Icos Corporation Platelet-activating factor acetylhydrolase
US5656431A (en) * 1993-10-06 1997-08-12 Icos Corporation Platelet-activating factor acetylhydrolase
US5847088A (en) * 1993-10-06 1998-12-08 Icos Corporation Antibodies specific for platelet-activating factor acetylhydrolase
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
EP0859834A2 (de) * 1995-09-29 1998-08-26 Smithkline Beecham Plc Paf-acetylhydrolase und ihre therapeutische verwendung
JPH11514228A (ja) * 1995-09-29 1999-12-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポ蛋白結合ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）ＰＡＦアセチルヒドロラーゼに対して配列相同性を有する化合物
EP0869943A1 (de) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclische beta-lactame zur behandlung von atherosklerose
WO1997035567A1 (en) * 1996-03-26 1997-10-02 Smithkline Beecham Corporation Pla2 inhibitors of angiogenesis
CZ341098A3 (cs) * 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
EP0883811A1 (de) * 1996-09-20 1998-12-16 Atherogenics Inc. Diagnose für und mediatoren von entzündungskrankheiten
WO1999009147A1 (en) * 1997-08-13 1999-02-25 Icos Corporation Truncated platelet-activating factor acetylhydrolase
EP1124970A1 (de) * 1998-10-28 2001-08-22 Smithkline Beecham Plc Reiningungsverfahren für phospholipase a2, die an ldl assoziiert ist, mittels affinitätschromatographie an immobilisierten metallen
PL209824B1 (pl) 2000-02-16 2011-10-31 Smithkline Beecham Plc 1-(N-2-(dietyloamino)etylo)-N-(4-(4-trifluorometylo-fenylo)benzylo)aminokarbonylometylo)-2-(4-fluorobenzylo)tio-5,6-trimetylenopirymidyn-4-on, jego zastosowania i zawierająca go farmaceutyczna kompozycja
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
TWI314457B (de) * 2001-03-19 2009-09-11 Shionogi & Co
US7468266B2 (en) * 2001-05-30 2008-12-23 Ryogen, Llc Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
US20040018533A1 (en) * 2002-06-04 2004-01-29 Adam Gail Isabel Reid Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
US20050239077A1 (en) * 2002-06-27 2005-10-27 Adam Gail I R Diagnosing predisposition to fat deposition and associated conditions
JP2006508642A (ja) * 2002-06-27 2006-03-16 ハークネス ファーマシューティカルズ，インコーポレイティド 脂肪の蓄積を減少させる方法と、関連疾患を治療するための方法
WO2004089184A2 (en) * 2003-04-01 2004-10-21 Diadexus, Inc. NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK
US7531316B2 (en) * 2003-05-28 2009-05-12 Glaxo Group Limited High throughput assay of Lp-PLA2 activity
US20070281323A1 (en) * 2004-02-03 2007-12-06 Wolfert Robert L Methods Of Detecting Lp-PLA2 Activity
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
US7741020B2 (en) * 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20070149001A1 (en) * 2005-12-22 2007-06-28 Uka Harshad K Flexible circuit
WO2007092735A2 (en) 2006-02-02 2007-08-16 Innovative Bio Therapies An extracorporeal cell-based therapeutic device and delivery system
EP2152865B1 (de) 2007-05-11 2015-04-15 Thomas Jefferson University Verfahren zur behandlung und vorbeugung neurodegenerativer krankheiten und störungen
AU2008251467B2 (en) * 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
AU2009327485A1 (en) 2008-06-18 2010-06-24 Cytopherx, Inc. Methods for propagation of renal precursor cells
JP5855055B2 (ja) * 2008-07-28 2016-02-09 キヤノン株式会社 化合物、ナノ粒子−分散剤複合体、ナノ粒子分散液およびナノ粒子−マトリックス材料複合体、化合物の製造方法
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
RU2513194C1 (ru) * 2013-01-31 2014-04-20 Федеральное государственное бюджетное учреждение "Научный центр неврологии" Российской академии медицинских наук (ФГБУ "НЦН" РАМН) Способ выявления развития гиперплазии неоинтимы и рестеноза сонных артерий после ангиореконструктивных операций на них у больных с прогрессирующим церебральным атеросклерозом
US20140283157A1 (en) * 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
CN106957824B (zh) * 2016-12-27 2018-02-23 南京诺唯赞医疗科技有限公司 耐脂蛋白干扰的抗人Lp‑PLA2蛋白的单克隆抗体及其应用
US10954255B2 (en) 2017-08-03 2021-03-23 Karl-Franzens-Universitaet Graz Phospholipid analogues
CN112210012A (zh) * 2020-10-12 2021-01-12 南京佰抗生物科技有限公司 高特异性和强亲和力的抗人Lp-PLA2蛋白的单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851819B (de) * 1984-08-17 1985-11-26 Wyeth John & Brother Ltd
US5373095A (en) * 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
US4917826A (en) * 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5081147A (en) * 1990-03-15 1992-01-14 Allergan, Inc. 4-(1-hydroxy-2-substituted amino)ethyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
WO1989009818A1 (en) * 1988-04-15 1989-10-19 Biogen, Inc. Processes for purifying phospholipase a2 and producing phospholipase a2-like polypeptides
JPH0265781A (ja) * 1988-08-29 1990-03-06 Shionogi & Co Ltd ヒト膵蔵ホスホリパーゼａ↓２の製造法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108899A (en) * 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
US5622832A (en) 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
JPH03258749A (ja) * 1990-03-07 1991-11-19 Ono Pharmaceut Co Ltd ベンゾフェノン誘導体、それらの製造方法、およびそれらを含有する薬剤
US5081261A (en) * 1990-03-23 1992-01-14 Allergan, Inc. 4-(1-hydroxy-2-N-substituted sulfonamido) ethyl-5-hydroxy-2(5H)-furanones and 4-(N-substituted sulfonamido)-2-ethenyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL101507A0 (en) * 1991-04-17 1992-12-30 Lilly Co Eli Compounds,vectors and methods for expressing human,cytosolic phospholipase a2
JP3036883B2 (ja) 1991-05-24 2000-04-24 株式会社シノテスト 血小板活性化因子アセチルヒドロラーゼ活性の測定法
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
JP3258749B2 (ja) 1993-03-10 2002-02-18 株式会社東芝 感潮運河の浄化方法および浄化装置
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham Plc An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
JPH0759597A (ja) 1993-08-23 1995-03-07 Shinotesuto:Kk 血小板活性化因子アセチルヒドロラーゼ活性測定方法
US5847088A (en) 1993-10-06 1998-12-08 Icos Corporation Antibodies specific for platelet-activating factor acetylhydrolase
ATE315655T1 (de) 1993-10-06 2006-02-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
US5656431A (en) 1993-10-06 1997-08-12 Icos Corporation Platelet-activating factor acetylhydrolase
US6146625A (en) 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
US5977308A (en) 1993-10-06 1999-11-02 Icos Corporation Platelet-activating factor acetylhydrolase
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
JPH11514228A (ja) 1995-09-29 1999-12-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポ蛋白結合ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）ＰＡＦアセチルヒドロラーゼに対して配列相同性を有する化合物
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JPH1017600A (ja) 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
CA2285384C (en) 1997-03-28 2012-10-16 Epitope, Inc. Simultaneous collection of dna and non-nucleic analytes from oral fluids
WO1999009147A1 (en) 1997-08-13 1999-02-25 Icos Corporation Truncated platelet-activating factor acetylhydrolase
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
EP1124970A1 (de) 1998-10-28 2001-08-22 Smithkline Beecham Plc Reiningungsverfahren für phospholipase a2, die an ldl assoziiert ist, mittels affinitätschromatographie an immobilisierten metallen
JP4220603B2 (ja) 1998-12-02 2009-02-04 アルフレッサファーマ株式会社 血小板活性化因子アセチルヒドロラーゼ活性の測定方法
GB0027181D0 (en) 2000-11-04 2000-12-27 S P A New use

Also Published As

Publication number Publication date
US20030148398A1 (en) 2003-08-07
EP0658205B1 (de) 2000-03-15
US7217535B2 (en) 2007-05-15
US5968818A (en) 1999-10-19
US20120045774A1 (en) 2012-02-23
US6369045B1 (en) 2002-04-09
US8088886B2 (en) 2012-01-03
US7045329B2 (en) 2006-05-16
US6177257B1 (en) 2001-01-23
US20050260731A1 (en) 2005-11-24
JPH08500740A (ja) 1996-01-30
US7314742B2 (en) 2008-01-01
US20090136969A1 (en) 2009-05-28
EP0974663A1 (de) 2000-01-26
US7416853B2 (en) 2008-08-26
US5981252A (en) 1999-11-09
DE69423436T2 (de) 2000-09-07
US20060040371A1 (en) 2006-02-23
US7052862B2 (en) 2006-05-30
US20020177209A1 (en) 2002-11-28
US20050106611A1 (en) 2005-05-19
EP0658205A1 (de) 1995-06-21
WO1995000649A1 (en) 1995-01-05
US20030186421A1 (en) 2003-10-02
US20070077251A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
DE69423436T2 (de) An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
DE29705934U1 (de) Diagnose- und Behandlungsvorrichtung für Zähne
DE69720058D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE69726195D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
KR950703893A (ko) 검사용 첩부제 및 검사방법(diagnostic patch and method for diagnosis using the same)
DE69430164D1 (de) Röntgenstrahlabbildunggerät und Verfahren für Diagnosezwecke
NO982156D0 (no) Diagnostisk pr÷veinnretning
DE69719741D1 (de) Zahnpflegegerät für haustiere und verfahren zu dessen herstellung
DE69435088D1 (de) Therapeutische und diagnostische mittel für die amyloidosis
DE59508991D1 (de) Vorrichtung für Bodenpflegegeräte
DE69716838D1 (de) Diagnostisches Mittel für Diabetes
DE69504591D1 (de) Ophthalmologisches Gerät für Fundusbilderzeugung
DE69304367T2 (de) Röntgenstrahlgerät für medizinischen Gebrauch
DE68926638T2 (de) Fehlerdiagnosesystem für Anlagen
DE69629813D1 (de) Orale feste diagnostische mahlzeit und verfahren für ihre verwendung
DE69605954D1 (de) Anti-Streuungs-Röntgenstrahlungs-Gittervorrichtung für medizinische diagnostische Radiographie und Verfahren zur Gitterherstellung
DE69413876T2 (de) Diagnoseverfahren für Garnwächter und Vorrichtung dazu
DE69821082D1 (de) Abbildungsvorrichtung und Verfahren für Computertomographie
DE69333765T8 (de) Medizinischer Laser und dessen Verwendung in einem Gerät für Diagnose und Therapie
DE69622759T2 (de) Streuungs-filter für emissionstomographie
FI963638A0 (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
DE69705918D1 (de) Fehlerdiagnosevorrichtung
DE69627238D1 (de) Gerät und Methode für überlappende Aufzeichnung
DE69514003T2 (de) Testverfahren für katheterbedingte sepsis
DE59501107D1 (de) Behandlungsvorrichtung für textile warenbahnen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition